The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Genomics Core Facility (GCF) is tasked with providing state-of-the-art genomics data generation services to University of Chicago faculty in a fee-for-service model. UCCCC members? fees are subsidized by the Cancer Center Support Grant (CCSG) via a co-pay mechanism. At present, the GCF main services are next-generation sequencing, DNA microarray analysis, and Sanger sequencing. The GCF also provides data storage services to its clients and partners with the Bioinformatics Core Facility (BiCF) for genomic data analysis. The GCF is organized into two Subcores, Next-Generation Sequencing and Microarrays Subcore, and DNA Sequencing and Genotyping Subcore, and has been located on the first floor of the Knapp Center for Biomedical Discovery (KCBD) since 2009. The GCF is directed scientifically by Yoav Gilad, PhD, Professor of Human Genetics, and operationally by Pieter Faber, PhD, with the assistance of William Buikema, PhD, as Technical Director of the DNA Sequencing and Genotyping Subcore. In addition to the leadership, the GCF employs nine technologists (six in the Next- Generation Sequencing and Microarrays Subcore, and three in the DNA Sequencing and Genotyping Subcore). Core developments in the current funding period include increased emphasis on next-generation sequencing (NGS) services to meet demand and advancements in the field. The main operating instruments of the Facility include Applied Biosystems 3730xl DNA analyzers (DNA Sequencing and Genotyping Subcore), an Illumina HiScan, and an Affymetrix GeneScan3000 microarray scan system, as well as three Illumina next- generation sequencing instruments (HiSEQ4000, HiSEQ2500, and a NextSeq500; Next-Generation Sequencing and Microarrays Subcore). The GCF effectively serves users? needs, and the services provided using these instruments occupy 80-90% of the available instrument and/or personnel time, indicating that staffing and instrumentation are operating and maintained at an appropriate level. UCCCC members receive priority, and projects are prioritized based on sample reception date and project urgency. To direct operations, Drs. Gilad and Faber meet on a biweekly basis, discussing any operational issues, as well as short-term and long-term strategies. Additionally, Drs. Gilad and Faber meet regularly with the GCF Faculty Oversight Committee (FOC) to receive constructive feedback from expert users in the genomics field. To best serve users? needs and gauge user satisfaction, the University of Chicago Office of Shared Research Facilities under the leadership of George Langan, DVM, conducts annual on-campus user surveys. The most recent survey from August 2016 showed a high approval rating (approximately 80%), with 99% of responders predicting continued use of the Facility in the future. New services will be added as needed (e.g., the Facility intends to add single cell RNA-SEQ to its repertoire (DROP-SEQ protocol) in 2017).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014599-43
Application #
9489793
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-22
Budget End
2019-03-31
Support Year
43
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966
Sample, Ashley; Zhao, Baozhong; Wu, Chunli et al. (2018) The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochem Photobiol 94:432-437
Hrusch, C L; Manns, S T; Bryazka, D et al. (2018) ICOS protects against mortality from acute lung injury through activation of IL-5+ ILC2s. Mucosal Immunol 11:61-70
Hope, C Matthew; Webber, Jemma L; Tokamov, Sherzod A et al. (2018) Tuned polymerization of the transcription factor Yan limits off-DNA sequestration to confer context-specific repression. Elife 7:
Wong, Gabrielle S; Zhou, Jin; Liu, Jie Bin et al. (2018) Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition. Nat Med 24:968-977
Wu, Chengyue; Pineda, Federico; Hormuth 2nd, David A et al. (2018) Quantitative analysis of vascular properties derived from ultrafast DCE-MRI to discriminate malignant and benign breast tumors. Magn Reson Med :
Meisel, Marlies; Hinterleitner, Reinhard; Pacis, Alain et al. (2018) Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557:580-584
Ni, Kaiyuan; Lan, Guangxu; Chan, Christina et al. (2018) Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun 9:2351
Wei, Jiangbo; Liu, Fange; Lu, Zhike et al. (2018) Differential m6A, m6Am, and m1A Demethylation Mediated by FTO in the Cell Nucleus and Cytoplasm. Mol Cell 71:973-985.e5

Showing the most recent 10 out of 668 publications